Revolution Medicines, Inc.
NASDAQ:RVMDBiotechnology
+$3.60 today
- Market cap
- $34.57B
- Beta
- 1.41
- P/E (TTM)
- -23.3
- EPS (TTM)
- -$6.92
Volume 2.34M
Average 3.10M
RVMD Weighted Avg Shares
Average number of basic shares outstanding during the period, used to calculate basic EPS.
Revolution Medicines, Inc.NASDAQ: RVMD
Weighted Avg Shares · Q2 FY2026 · quarter ended Jun 2026
Weighted avg shares grows in line with its trailing trend
Q2 FY2026 weighted avg shares of 210.89M shares rose 12.1% year over year, ahead of the +10.9% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 6.5% from the prior quarter. Over 3 fiscal years it compounded at +33.1% a year.
Context
- Weighted avg shares increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +12.1% holds above the trailing-twelve-month pace of +10.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares history
Shares · from the income statement
- Latest · FY2025
- 190.13M USD
- Year-over-year change
- +13.3%
- 4-year CAGR
- +27.1%
| Period | Period end | Weighted Avg Shares | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 190.13M | +13.3% |
| FY2024 | 2024-12-31 | 167.74M | +48.2% |
| FY2023 | 2023-12-31 | 113.15M | +40.3% |
| FY2022 | 2022-12-31 | 80.63M | +10.7% |
| FY2021 | 2021-12-31 | 72.81M | — |
Weighted Avg Shares vs competitors
How RVMD compares with its peers on the latest reported figures
- RVMD's LTM Jun 2026 weighted avg shares of 197.09M shares is the 2nd highest of the 11 companies compared; the peer median is 90.72M shares.
- Its year-over-year change of +10.9% is the 7th highest of 11, against a peer median of +17.6%.
- Over three fiscal years its annual growth of +33.1% compares with a peer median of +25.0%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Sep 2026 | 310.86M | +9.7% | +32.5% | |
| LTM Jun 2026 | 197.09M | +10.9% | +33.1% | |
| LTM Jun 2026 | 181.67M | +12.1% | +15.2% | |
| LTM Sep 2026 | 145.89M | +32.5% | +9.8% | |
| LTM Aug 2026 | 106.95M | +29.6% | +21.3% | |
| LTM Mar 2026 | 92.59M | +31.1% | +30.3% | |
| LTM Mar 2026 | 88.85M | +4.6% | +28.8% | |
| LTM Mar 2026 | 80.25M | +101.5% | +62.5% | |
| LTM Mar 2026 | 73.92M | -0.4% | +20.7% | |
| LTM Sep 2026 | 65.9M | +23.1% | +108.5% | |
| LTM Mar 2026 | 56.95M | +1.3% | +16.2% | |
| Peer median (excluding RVMD) | 90.72M | +17.6% | +25.0% | |
Competitors are the stored peer set for RVMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 29.39M | 35.38M | 11.58M | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 16.56M |
| Gross Profit | 29.39M | 35.38M | 11.58M | 0 | (16.56M) |
| Gross Margin | 100.0% | 100.0% | 100.0% | — | — |
| Research & Development | 186.95M | 253.07M | 423.14M | 592.23M | 978.68M |
| Selling, General & Admin | 30.45M | 40.59M | 75.62M | 97.3M | 187.13M |
| Operating Expenses | 217.4M | 293.66M | 498.77M | 689.52M | 1.17B |
| Depreciation & Amortization | 7.33M | 9.66M | 9.31M | 11.82M | 16.56M |
| EBITDA | (179.75M) | (239.47M) | (430.28M) | (589.02M) | (1.09B) |
| EBITDA Margin | -611.6% | -676.8% | -3715.7% | — | — |
| Operating Income | (188.01M) | (258.28M) | (487.19M) | (689.52M) | (1.18B) |
| Operating Margin | -639.7% | -730.0% | -4207.1% | — | — |
| Interest Income | 929K | 9.15M | 47.48M | 86.88M | 90.69M |
| Interest Expense | 12K | 0 | 303K | 0 | 24.23M |
| Other Income / Expenses | 917K | 9.15M | 47.29M | 88.68M | 51.07M |
| Income Before Tax | (187.09M) | (249.13M) | (439.89M) | (600.85M) | (1.13B) |
| Pre-Tax Margin | -636.6% | -704.1% | -3798.7% | — | — |
| Income Tax Expense | 0 | (420K) | (3.52M) | (753K) | 0 |
| Net Income | (187.09M) | (248.71M) | (436.37M) | (600.09M) | (1.13B) |
| Net Margin | -636.6% | -703.0% | -3768.3% | — | — |
| EPS (Basic) | (2.47) | (3.08) | (3.86) | (3.58) | (5.95) |
| EPS (Diluted) | (2.47) | (3.08) | (3.86) | (3.58) | (5.95) |
| Weighted Avg Shares | 72.81M | 80.63M | 113.15M | 167.74M | 190.13M |
| Weighted Avg Shares (Diluted) | 72.81M | 80.63M | 113.15M | 167.74M | 190.13M |
Revolution Medicines, Inc.
NASDAQ:RVMD
Intrinsic Alpha fair value
Locked
Current Price
$159.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.